PP118. Is the placental mass associated with the severity of preeclampsia?

M Baumann1, M Marti1, L Durrer1

  • 1Obstetrics and Gynecology, University Hospital of Bern, Bern, Switzerland.

Insights

Placental mass does not correlate with preeclampsia severity. Maternal response, not placental size, likely dictates disease progression after initial triggers.

Area of Science:

  • Obstetrics and Gynecology
  • Perinatal Medicine
  • Pathophysiology

Background:

  • Preeclampsia (PE) is a significant cause of maternal and fetal morbidity and mortality.
  • The placenta is believed to play a crucial role in PE pathogenesis, though its exact mechanisms remain unclear.

Purpose of the Study:

  • To investigate the relationship between placental mass and the clinical severity of preeclampsia.
  • To determine if placental weight influences the manifestation of moderate, severe PE, and HELLP syndrome.

Main Methods:

  • Analysis of 208 placentae from singleton pregnancies with preeclampsia.
  • Comparison of placental weights, adjusted for gestational age using the observed/expected (O/E) ratio.
  • Statistical analysis using Chi-squared and Kruskal-Wallis tests (p<0.05 significance).

Main Results:

  • Most placentae (69.2%) weighed below the 10th percentile.
  • While mean placental weights differed between PE severity groups, these differences were not statistically significant after adjusting for gestational age (O/E ratio).
  • Severe PE and early delivery were strongly associated.

Conclusions:

  • Placental mass is not significantly associated with preeclampsia severity.
  • Maternal factors, rather than placental size, are hypothesized to modulate PE severity once initiated by placental factors.
Abstract

Related Concept Videos

Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
535
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.6K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.5K
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
951